Clostridium difficile Infection (CDI) by Hypervirulent BI/NAP1/027 Strain: a Comprehensive Review of Toxigenicity, Pathogenesis, Risk Factors, and Preventative Measures
Downloads
Clostridium difficile is an anaerobic bacil gram-positive bacteria, able to form spores and toxin, that is transmitted among humans through the fecal–oral route. Clostridium difficile infection (CDI), a typical nosocomial infection has been contributed to a signiï¬ cant proportion of morbidity and mortality among in-patients with a case-fatality rate of 14% within 30 days after diagnosis. Profound culture and toxin examination for C. difficile are still minimal in many hospitals in various Asian countries. Consequently, C. difficile reports in Asia remain rare. Highly virulent form of C. difficile caused greater fatality and epidemics severity. Elderly age, hospitalization, exposure to antibiotics e.g., cephalosporins, fluoroquinolones, clindamycin, and penicillin contributed as main risk factors. Hypervirulent strain BI/NAP1/027 demonstrated to carry CdtLoc gene locus encodes CD196 ADP-ribosyltransferase (CDT) or known as binary toxin. Virulence factors are TcdA, TcdB, CDTa CDTb in which hypersporulation and mutation of TcD gene by hypervirulent strain led to toxin hyperexpression. Early cases detection, building management team to evaluate patient positive with all C. difficile toxins, hand hygiene improvement, continuation of contact precautions after diarrhea resolution, audit of infection control, and restriction of antimicrobials should be implemented as preventative measures. Focus measures also should emphasize on development of vaccine of C. difficile to boost immune state of elderly people. This review aims to describe severity of disease caused by hypervirulent BI/NAP1/027 C. difficile strain, its mechanism or pathogenesis, risk factors, current treatment options available, along with proposed preventative measures and infection control.
Kotila SM, Mentula S, Ollgren J, VirolainenJulkunen A, Lyytikäinen O. Community- and Healthcare-Associated Clostridium difficile Infections, Finland, 2008−2013. Emerging Infectious Disease journal. [Online] 2016;22(10): 1747. Available from: doi:10.3201/eid2210.151492
Banaei N, Anikst V, Schroeder LF. Burden of Clostridium difficile infection in the United States. [Online] The New England Journal of Medicine. United States; 2015. p. 2368–2369. Available from: doi:10.1056/NEJMc1505190#SA2
Lucado J, Gould C, Elixhauser A. Clostridium Difficile Infections (CDI) in Hospital Stays, 2009: Statistical Brief #124. Rockville (MD); 2006.
Collins DA, Hawkey PM, Riley T V. Epidemiology of Clostridium difficile infection in Asia. Antimicrobial resistance and infection control. [Online] England; 2013;2(1): 21. Available from: doi:10.1186/20472994-2-21
Putsathit P, Maneerattanaporn M, Piewngam P, Kiratisin P, Riley T V. Prevalence and molecular epidemiology of Clostridium difficile infection in Thailand. New Microbes and New Infections. [Online] Elsevier Ltd; 2017;15: 27–32. Available from: doi:10.1016/j.nmni.2016.10.004
Rupnik M, Grabnar M, Geric B. Binary toxin producing Clostridium diffi cile strains. Anaerobe. [Online] England; 2003;9(6): 289–294. Available from: doi:10.1016/j.anaerobe.2003.09.002
Oyofo BA, Subekti D, Tjaniadi P, Machpud N, Komalarini S, Setiawan B, et al. Enteropathogens associated with acute diarrhea in community and hospital patients in Jakarta, Indonesia. FEMS immunology and medical microbiology. England; 2002;34(2): 139–146.
Collins DA, Gasem MH, Habibie TH, Arinton IG, Hendriyanto P, Hartana AP, et al. Prevalence and molecular epidemiology of Clostridium difficile infection in Indonesia. New Microbes and New Infections. [Online] Elsevier Ltd; 2017;18: 34–37. Available from: doi:10.1016/j.nmni.2017.04.006
Rupnik M. Clostridium difficile : (Re)emergence of Zoonotic Potential. Clinical Infectious Diseases. [Online] 2010;51(5): 583–584. Available from: doi:10.1086/655693
Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. The New England journal of medicine. [Online] United States; 2000;342(6): 390–397. Available from: doi:10.1056/ NEJM200002103420604
Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet (London, England). [Online] England; 2001;357(9251): 189–193. Available from: doi:10.1016/S0140-6736(00)03592-3
Pepin J, Saheb N, Coulombe M-A, Alary M-E, Corriveau M-P, Authier S, et al. Emergence of fl uoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clinical infectious diseases : an offi cial publication of the Infectious Diseases Society of America. [Online] United States; 2005;41(9): 1254–1260. Available from: doi:10.1086/496986
Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. The Journal of infection. [Online] England; 2009;58(6): 403–410. Available from: doi:10.1016/j. jinf.2009.03.010
Hoyert DL, Xu J. Deaths: preliminary data for 2011. National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. [Online] 2012;61(6): 1–51. Available from: http:// www.ncbi.nlm.nih.gov/pubmed/24984457
Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. The American journal of gastroenterology. [Online] United States; 2012;107(1): 89–95. Available from: doi:10.1038/ajg.2011.398
Dumyati G, Stevens V, Hannett GE, Thompson AD, Long C, MacCannell D, et al. Community-associated Clostridium difficile Infections, Monroe County, New York, USA. Emerging Infectious Diseases. [Online] Centers for Disease Control and Prevention; 2012;18(3): 392–400. Available from: doi:10.3201/ eid1803.102023
Khurana A, Vinayek N, Recco RA, Go ES, Zaman MM. The incidence of Clostridium difficile-associated and non-C. difficile-associated diarrhea after use of gatifl oxacin and levofl oxacin in an acute-care facility. [Online] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. United States; 2004. p. 602–603. Available from: doi:10.1086/422525
Ho J, Dai RZW, Kwong TNY, Wang X, Zhang L, Ip M, et al. Disease Burden of Clostridium difficile Infections in Adults, Hong Kong, China, 2006-2014. Emerging infectious diseases. [Online] 2017;23(10): 1671–1679. Available from: doi:10.3201/eid2310.170797
Kim YS, Han DS, Kim YH, Kim WH, Kim JS, Kim HS, et al. Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study. Epidemiology and infection. [Online] England; 2013;141(1): 189–194. Available from: doi:10.1017/ S0950268812000581
Marsh JW, Arora R, Schlackman JL, Shutt KA, Curry SR, Harrison LH. Association of Relapse of Clostridium difficile Disease with BI/NAP1/027. Journal of Clinical Microbiology. [Online] 1752 N St., N.W., Washington, DC: American Society for Microbiology; 2012;50(12): 4078–4082. Available from: doi:10.1128/JCM.02291-12
Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clinical infectious diseases. [Online] 2002;34(3): 346–353. Available from: doi:10.1086/338260
Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective. The Journal of infection. [Online] England; 2013;66(2): 115–128. Available from: doi:10.1016/j.jinf.2012.10.019
Sitzlar B, Vajravelu RK, Jury L, Donskey CJ, Jump RLP. Environmental decontamination with ultraviolet radiation to prevent recurrent Clostridium diffiicile infection in 2 roommates in a long-term care Facility. [Online] Infection control and hospital epidemiology. United States; 2012. p. 534–536. Available from: doi:10.1086/665310
Guerrero DM, Nerandzic MM, Jury LA, Jinno S, Chang S, Donskey CJ. Acquisition of spores on gloved hands after contact with the skin of patients with Clostridium diffi cile infection and with environmental surfaces in their rooms. American journal of infection control. [Online] United States; 2012;40(6): 556–558. Available from: doi:10.1016/j.ajic.2011.08.002
Asempa TE, Nicolau DP. Clostridium difficile infection in the elderly: an update on management. Clinical Interventions in Aging. [Online] Dove Medical Press; 2017;12: 1799–1809. Available from: doi:10.2147/ CIA.S149089
Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infection control and hospital epidemiology. [Online] United States; 2010;31(5): 431–455. Available from: doi:10.1086/651706
Leffler DA, Lamont JT. Clostridium difficile Infection. New England Journal of Medicine. [Online] Massachusetts Medical Society; 2015;372(16): 1539– 1548. Available from: doi:10.1056/NEJMra1403772
Procop G, Church D, Hall G, Janda W, Koneman E, Schreckenberger P, et al. Koneman's Color Atlas and Textbook of Diagnostic Microbiology.. Seventh Ed. Joyce J (ed.) Philadelphia: Wolters Kluwer; 2017.
Mulvey MR, Boyd DA, Gravel D, Hutchinson J, Kelly S, McGeer A, et al. Hypervirulent Clostridium difficile strains in hospitalized patients, Canada. Emerging Infectious Diseases. [Online] 2010;16(4): 678–681. Available from: doi:10.3201/eid1604.091152
Hensgens MP, Keessen EC, Squire MM. Clostridium difficile infection in the community: a zoonotic disease?. Clin Microbiol Infect. 2012;18: 635-45. Available from: doi: 10.1111/j.1469-0691.2012.03853.x
Sachsenheimer FE, Yang I, Zimmermann O. Genomic and phenotypic diversity of Clostridium difficile during long-term sequential recurrence of infection. Int J Med Microbiol. 2018;308: 364-77. Available from: doi:10.1016/j.ijmm.2018.02.002
Luciano JA, Zuckerbraun BS. Clostridium difficile infection: prevention, treatment, and surgical management. Surg Clin North Am. 2014;94: 1355-49. Available from: doi:10.1016/j.suc.2014.08.006
Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis. 1992;166: 561-67. Available from: https://www.jstor. org/stable/30113322
Howell M, Novack V, Grgurich P, Soulliard D, Novack L, Pendina M, Talmor D. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170: 784-90. Available from: doi:10.1001/archinternmed.2010.89
O'Keefe S. Tube feeding, the microbiota, and Clostridium difficile infection. World J Gastroenterol. 2010;16: 139-42. Available from: doi:10.3748/wjg. v16.i2.139
Hampton T. Report reveals scope of US antibiotic resistance threat. JAMA. 2013;310: 1661-63. Available from: doi: 10.1001/jama.2013.280695
Popoff MR, Rubin EJ, Gill DM. Actin-speciï¬ c ADPribosyltransferase produced by a Clostridium difficile strain. Infect Immun. 1998;56: 2299-2306. Available from: doi: 10.1128/iai.56.9.2299-2306.1988
Jamal W, Rotimi VO, Brazie J, Duerden BI. Analysis of prevalence, risk factors and molecular epidemiology of Clostridium difficile infection in Kuwait over a 3-year period. Anaerobe. 2010;16: 560-65. Available from: doi:10.1016/j.anaerobe.2010.09.003
Jalali M, Khorvash F, Warriner K, Weese J. Clostridium difficile infection in an Iranian hospital. BMC Res Notes. 2012;5: 159. Available from: 10.1186/17560500-5-159
Al-Thani AA, Hamdi WS, Al-Ansari NA, Doiphode SH, Wilson GJ. Polymerase chain reaction ribotyping of Clostridium difficile isolates in Qatar: a hospitalbased study. BMC Infect Dis. 2014;14: 502. Available from: doi:10.1186/1471-2334-14-502
Bauer KA, Johnston JEW, Wenzler E. Impact of the NAP-1 strain on disease severity, mortality, recurrence of healthcare-associated Clostridium difficile infection. Anaerobe. 2017;48: 1-6. Available from: doi:10.1016/j.anaerobe.2017.06.009
Sirard S, Valiuette L, Fortier LC. Lack of asscociation between clinical outcome of Clostridium difficile infetions, strain type, and virulence-associated phenotypes. J Clin Microbiol. 2011;49: 4040-46. Available from: doi:10.1128/jcm/05053-11
Rao K, Micic D, Natarajan M. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clin Infect Dis. 2015;61: 233-41. Available from: doi:10.1093/cid/civ254
See I, Mu Y, Cohen J. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis. 2014;58: 1394-400. Available from: doi:10.1093/cid/ciu125
Merrigan M, Sambol S. Johnson. Susceptibility to hamsters to human pathogenic Clostridium difficile strain B1 following clindamycin, ampicillin or ceftriaxone administration. Anaerobe. 2003;9: 91-95. Available from: doi:10.1016/s10759964(03)00063-5
Marsh JW. Association of relapse of Clostridium difficile disease with BI/NAP1/027. J Clin Microbiol. 2012;50: 4078-4082. Available from: doi:10.1128/ jcm.02291-12
Pepin J, Valiquette L, Alary ME. Clostridium difficileassociated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171: 466-472. Avalaible from: doi:10.1503/ cmaj.1041104
Hubert B, Loo VG, Bourgault AM. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-ï¬ eld type 1 strain and the epidemiology of C. difficile-assocated disease in Quebec. Clin Infect Dis. 2007;44: 238-44. Available from: doi:10.1086/510391
Yakob L, Riley TV, Paterson DL, Marquess J, Magalhaes RJS, Kanamori LF, Clements ACA. Mechanisms of hypervirulent Clostridium difficile ribotype 027 displacement of endemic: an epidemiological model. Nature Scientiï¬ c Report. 2019;5: 12666. Available from: doi: 10.1038/srep12666.
Cheng V, Yam W, Lam O. Clostridium difficile isolates with increased sporulation: emergence of PCR ribotype 002 in Hong Kong. Eur J Clin Microbiol Infect Dis. 2011;30: 1371-81. Available from: doi:10.1007/ s10096-011-1231-0
Kim H, Lee Y, Moon H, Lim C, Lee K, Chong Y. Emergence of Clostridium difficile ribotype 027 in Korea. Korean J Lam Med. 2011;31: 191-96. Available from:doi: https://dx.doi.org/10.3343%2Fkjlm.2011.3 1.3.191
Krutova M, Nyc O, Matejkova J, Kuijper E, Jalava I, Mentula S. The recognition and characterisation of Finnish Clostridium difficile isolates resembling PCR-ribotype 027. J Microbiol Immunol Infect. 2018;51: 344-51. Available from: doi:10.1016/j. jmii.2017.02.002
Freeman J, Vernon J, Pilling S. The CloseER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotype, 2011-2014. Clin Microbiol Infect. 2018;24: 724-31. Available from: doi:10.1016/j.cmi.2017.10.008
Giancola S, Williams R, Gentry C. Prevalence of Clostridium difficile BI/NAP1/027 strain across the United States Veterans Health Administration. Clin Microbiol Infect. 2018;24: 877-81. Available from: 10.1016/j.cmi.2017.11.011
Pituch H, Obuch-Woszczatynski P, Lachowiz D. Prevalence of Clostridium difficile infection in hospitalized patients with diarhrhoea: results of a Polish multicenter, prospective, biannual pointprevalence study. Adv Med Sci. 2018;63: 290-95. Available from: doi:10.1016/j.advms.2018.03.003
Muto CA, Blank MK, Marsh JW. Control of an outbreak of infection with hypervirulent Clostridium difficile BI strain in a university using comprehensive "bundle” approach. Clin Infect Dis. 2007;45: 12661273. Available from: doi:10.1086/522654
DePestel DD, Aronoff DM. Epidemiology of Clostridium difficile infection. J Pharm Pract. 2013;26: 464-75. Available from: doi: 10.1177/0897190013499521
Gerding DN, Johnson S, Rupnik M, Aktories K. Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes. 2014;5: 15-27. Available from: doi: 10.4161/gmic.26854
Warny M, Pepin, Fang A. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366: 1079-84. Available from: doi: 10.1016/S0140-6736(05)67420-X
Akerlund T, Persson I, Unemo M, Noren T, Svenungsson B, Wult M, Burman LG. Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. J Clin Microbiol. 2008;46: 1530-33. Availabe from: doi: 10.1128/JCM.01964-07
Cloud J, Noddin L, Pressman A, Hu M, Kelly C. Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clin Gastroeneterol Hepatol. 2009;7: 868-873.e2. Available from: doi: 10.1016/j.cgh.2009.05.018
Morgan OW, Rodrigues B, Elston T, Verlander NQ, Brown DF, Brazier J, Reacher M. Clinical severity of Clostridium difficile PCR ribotype 027: a case study. PLoS One. 2008;3: e1812-10. Availabe from: doi:10.1371/journal.pone.0001812
Walk ST, Mimic D, Jain R. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis. 2012; 55: 1661-68. Available from: doi:10.1093/ cid/cis786
Sirard S, Valiquette L, Forties LC. Lack of association bertween clinical outcome of Clostridium difficile infections, strains type, and virulence-associated phenotypes. J Clin Microbiol. 2011; 49:4040-46. Availabe from: doi:10.1128/jcm.05053-11
Hsu J, Abad C, Dinh M, Safdar N. Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am J Gastroenterol. 2010;105: 2327-39. Available from: doi:10.1038/ ajg.2010.254
Secore S, Wang S, Doughtry J. Development of a novel vaccine containing binary toxin for prevention of Clostridium difficile disease with enhanced effi cacy against NAP1 strains. PLoS One. 2017;12: e0170640. Available from: doi:10.1371/journal.pone.0170640
Kokai-Kun JF, Roberts T, Coughlin O. The oral β-lactamase SYN-004 (ribaxamase) degrades ceftriaxone excreted into the intestine in phase 2a clinical studies. Antimicrob Agents Chemother. 2017;61: e02197-16. Available from: doi:1128/ aac.02197-16
Karlowsky JA, Adam HJ, Kosowan T. PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium diffi cile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium diffi cile Surveillance Study (CAN-DIFF) 2013-2015. Diagn Microbiol Infect Dis. 2018;91: 105-11. Available from: doi:10.1016/j.diagmicrobio.2018.01.017
Vickers RJ, Tillotson GS, Nathan R. Effi cacy and safety and ridinilazole compared with vancomycin for the treatment of Clostridium diffi cile infection: a phase 2, randomised, double-blind, activecontrolled, and non-inferiority study. Lancet Infect Dis. 2017;17: 735-44. Available from: doi:10.1016/ s1473-3099(17)30235-9
Coffman K, Chen XJC, Okamura C, Louie E. IVIG - A cure to severe refractory NAP-1 Clostridium difficile colitis? A case of successful treatment of severe infection, which failed standard therapy including fecal microbiota transplants and ï¬ daxomicin. IDCases. 2017;8: 27-28. Available from: doi:10.1016/j. idcr.2017.03.002
McDonald LC, Gerding DN, Johnson S. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66: e1-e48. Available from: doi:10.1093/cid/cix1085
Sawabe E, Kato H, Osawa K, Chida T, Tojo N, Arakawa Y, Okamura N. Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominance type over a ï¬ veyear period. Eur J Clin Microbiol Infect Dis. 2007;26: 695-703. Available from: doi: 10.1007/s10096-0070355-8
Copyright (c) 2022 Indonesian Journal of Tropical and Infectious Disease
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
